Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer
Author:
Affiliation:
1. Early Drugs Development for Innovative Therapies Division, European Institute of Oncology, Milan, Italy
2. Division of Senology, European Institute of Oncology, Milan, Italy
3. School of Medicine, University of Milano, Milan, Italy
Funder
No funding
Publisher
Informa UK Limited
Subject
Pharmacology,Toxicology,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/17425255.2017.1318848
Reference28 articles.
1. Targeting CDK4 and CDK6: From Discovery to Therapy
2. Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
3. Cyclin D-dependent kinases, INK4 inhibitors and cancer
4. CDK4: A Key Player in the Cell Cycle, Development, and Cancer
5. Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer;The Breast;2024-08
2. Pharmacodynamic characteristics, safety profile, and interactions of CDK4/6 inhibitors (CDK4/6i) in HR+/HER2– advanced/metastatic breast cancer;European Journal of Oncology Pharmacy;2024-04
3. Dalpiciclib. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, Treatment of HR+/HER2- and HER2+ advanced breast cancer;Drugs of the Future;2022
4. Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades;Pharmaceuticals;2021-07-22
5. CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions;International Journal of Molecular Sciences;2020-09-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3